{"analyses":[{"ciLowerLimit":"0.710","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.013","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0683","paramType":"Hazard Ratio (HR)","paramValue":"0.848","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval (CI) was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"52.4","upperLimit":"NA","value":"65.6"},{"groupId":"OG001","lowerLimit":"37.0","upperLimit":"65.8","value":"47.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"498"}],"units":"Participants"}],"description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"},{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.","id":"OG001","title":"Best Supportive Care (BSC)"}],"paramType":"MEDIAN","populationDescription":"Randomized ITT population was defined as all randomized participants with resected Stage IB \\[tumors ≥ 4 centimetres (cm)\\]-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to 95 months","title":"Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population","type":"PRIMARY","unitOfMeasure":"months"}